Condition: Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
This trial is a registrational Phase III, randomized, controlled, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-positive locally advanced or metastatic gastric or gastro-esophageal junction (G/GEJ) adenocarcinoma after failure of first-line anti-HER2 therapy and first-line standard chemotherapy.
This description comes directly from the study's public registry record.
Sa Xiao, PHD · 15013238943 · xiaosa@baili-pharm.com
Always discuss trial participation with your own doctor first.
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07152405